Development
Ocular Therapeutix, Inc.
OCUL
$8.23
-$0.105-1.26%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -5,562.79% | 97.51% | 31.78% | -95.07% | 35.74% |
| Total Depreciation and Amortization | 7.64% | 36.50% | 34.99% | -1.63% | -3.54% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 186.27% | -415.94% | -63.31% | 5,321.93% | -96.54% |
| Change in Net Operating Assets | -205.32% | 235.85% | -83.20% | -17.10% | -154.56% |
| Cash from Operations | -190.40% | 61.48% | -0.51% | -17.78% | -28.77% |
| Capital Expenditure | -77.22% | 86.98% | 41.11% | -57.16% | -170.78% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -77.22% | 86.98% | 41.11% | -57.16% | -170.78% |
| Total Debt Issued | -100.00% | -- | -100.00% | -- | -- |
| Total Debt Repaid | 100.00% | -- | 100.00% | -- | -- |
| Issuance of Common Stock | 13,948.05% | -92.02% | 12,265.38% | -82.97% | 22.46% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Financing | 108.28% | 438.47% | 12,265.38% | -82.97% | 22.46% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 94.01% | 453.82% | 46.64% | -24.79% | -37.24% |